Luis Raez, MD, FACP, FCCP, Memorial Healthcare System, Pembroke Pines, FL, provides an overview of management options for patient with non-small cell lung cancer (NSCLC), who have progressed on EGFR inhibitors. Half of patients will develop resistance to osimertinib via MET, HER2 or fusion mutations, which represent a great unmet need. Novel agents such as amivantamab, and lazertinib have showed encouraging efficacy in trials. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
